The recent close of $109.20 is approximately 238% above the fair value buy target for the stock and approximately 64% above the fair value close target for the stock. The recent close is also 10% below analysts' twelve-month $121.00 median price target for the stock.
The recent close represents a 30% increase in the year over year price of the stock, while for the same period sales increased 11%, earnings increased 17%, and debt decreased 43%.
The stock currently has a trailing twelve-month PE Ratio of 16, and a PEG Ratio of 1.9 basis estimated forward earnings growth of 8.5%.
In the past 52 weeks, share prices have moved between a high of $116.25 and a low of $80.60, placing equilibrium at $100.77.
Basis the recent close, the stock is trading 6.5% below the 52 week high, 26% above the 52 week low, and 8% above equilibrium.
The three-month average daily trading volume for the stock is approximately 3.4 million shares.
Amgen, Inc. is a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada.
The company's listed competitors include Johnson and Johnson, Novartis AGand Teva Pharmaceutical Industries Ltd
Financial information that may be contained herein, is based on the company's most recent annual SEC filing for year ending December 31, 2012.
All prices are per share unless otherwise noted.
Wax Ink currently has no investment position in any company mentioned in this alert.
For use by Accredited Investors as defined under Title 17, CFR §230.500, Regulation D.
Copyright © 2013 Wax Ink
Wax Ink is a baseline equity research company not licensed or registered with any government agency
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.